Virological and Immunological Response to HAART Therapy in a Community-Based Cohort of HIV-1-Positive Individuals

REFERENCES

• Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers. AIDS. 1997;11:F101–105.
   PubMed Web of Science ®Google Scholar
• PaleIla FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infections and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725–733.
   PubMed Web of Science ®Google Scholar
• Gullick RM, Mellors JW, Haylir D, et al. Treatment with indinavir, zidovudine, and lamivudine and prior antiretroviral therapy. N Engl J Med. 1997;337:734–739.
   PubMed Web of Science ®Google Scholar
• Pialoux G, Raffi F, Brun-Vezinet F, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1 infected patients. Trilege (Agence Nationale de Recherches sur la SIDA 072) Study Team. N Engl J Med. 1998;339:1269–1276.
   PubMed Web of Science ®Google Scholar
• BHIVA Guidelines Coordinating Committee. British HIV As-sociation guidelines for aniretroviral treatment of HIV se-ropositive individuals. Lancet. 1997;349:1086–1092.
   PubMed Web of Science ®Google Scholar
• Panel on Clinical Practices for Treatment of HIV Infection (convened by Department of Health and Human Services and Henry Kaiser Family Foundation). Guidelines for the use of antiretroviral agents in HIV-infected adults and ado-lescents. Ann Intern Med. 1997;128:1079–1100.
   Google Scholar
• Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. Update recommendations of the International AIDS Society-USA Panel. JAMA. 1998;280:78–86.
   PubMed Web of Science ®Google Scholar
• Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV infected patients with unde-tectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med. 1998;339:1261–1268.
   PubMed Web of Science ®Google Scholar
• Staszewski S, Miller V, Sabin C, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS. 1999;13:367–373.
   PubMed Web of Science ®Google Scholar
• Kaufman D, Pantaleo G, Sudre P, Telenti A, for the Swiss HIV Cohort Study. CD4 cell count in HIV-infected individu-als remaining viraemic with highly active antiretroviral therapy (HAART). Lancet. 1998;351:723–724.
   PubMed Web of Science ®Google Scholar
• Levitz S. Improvement in CD4+ cell counts despite persis-tently detectable HIV load. N Engl J Med. 1998;338:1074–1075.
   PubMed Web of Science ®Google Scholar
• Perrin L, Telenti A. HIV treatment failure: Testing for HIV resistance in clinical practice. Science. 1998;280:1871–1872.
   PubMed Web of Science ®Google Scholar
• Barreiro PM, Dona MC, Castilla J, Soriano V. Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral tharpy. AIDS. 1999;13:525–526.
   PubMed Web of Science ®Google Scholar
• Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS. 1999;13:1873–1880.
   PubMed Web of Science ®Google Scholar
• Wit FWNM, van Leeuwen R, Weverling GJ, et al. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immuno-deficiency virus type 1-infected persons. J Infect Dis. 1999;179:790–798.
   PubMed Web of Science ®Google Scholar
• Staszewski S, Miller V, Sabin C, et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS. 1999;13:951–956.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS. 1999;13:F35–F43.
   PubMed Web of Science ®Google Scholar
• Fatkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS. 1997;11:F113–F116.
   PubMed Web of Science ®Google Scholar
• Sande MA, Carpenter CC, Cobbs CG, Holmes KK, Sanford JP. Antiretroviral therapy for adult HIV-infected patients. Recommendations from a State-of-the-Art Conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-retroviral Therapy for Adult HIV-Infected Patients. JAMA. 1993;270:2583–2589.
   PubMed Web of Science ®Google Scholar
• Moyle G. Saquinavir: A review of its development, pharma-cological properties and clinical use. Exp Opin Invest Drugs. 1996;5:155–167.
   Google Scholar
• Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med. 1996;334:1011–1017.
   PubMed Web of Science ®Google Scholar
• Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS. 1998;12:F9—F14.
   PubMed Web of Science ®Google Scholar
• Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4 T cell homeostasis and function in advanced HIV disease. Science. 1997; 277:112–116.
   PubMed Web of Science ®Google Scholar
• Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV disease. Lancet. 1998;351:1682–1686.
   PubMed Web of Science ®Google Scholar
• Lederman M, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315. J Infect Dis. 1998;178:70–79.
   PubMed Web of Science ®Google Scholar
• Mitsuyasu R. HIV protease inhibitors: Immunological in-sights. AIDS. 1999;13\(suppl 1):S19—S27.
   PubMedGoogle Scholar
• Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS. 1998;11:745–750.
   Web of Science ®Google Scholar
• Li T, Tubiana F, Katlama C, Calvez V, Ait H, Austran B. Long-lasting recovery in CD4 T-cell function and viral load reduction after highly active antiretroviral therapy in ad-vanced HIV-1 disease. Lancet. 1998;351:1682–1686.
   PubMed Web of Science ®Google Scholar
• Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibi-tor-containing antiretroviral regimen. AIDS. 1999;13:669–676.
   PubMed Web of Science ®Google Scholar
• Cohen J. Failure isn't what it used to be ... but neither is success. Science. 1998;279:1133–1134.
   PubMed Web of Science ®Google Scholar
• Pakker NG, Kroon EDMB, Roos MTL, et al. Immune resto-ration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. AIDS. 1999;13:203–212.
   PubMed Web of Science ®Google Scholar